NAD+ Tirzepatide Side Effects: Clinical Evidence & Biomarkers

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

NAD+ tirzepatide side effects overlap substantially with standard tirzepatide, including nausea, vomiting, diarrhea, and injection-site reactions. The addition of NAD+ precursors aims to support mitochondrial function, though clinical evidence for NAD+-specific tolerability benefits remains limited and should be evaluated carefully with your provider.

Understanding potential side effects before starting any GLP-1/GIP therapy is critical for managing expectations and adherence. PlexusDx takes a precision-wellness approach: genetic and biomarker context can help identify which individuals may experience greater tolerability challenges, enabling providers to optimize dosing strategies, monitor metabolic markers, and make informed treatment adjustments.

What NAD+ Tirzepatide Actually Is — And Why Side Effect Profiles Matter

NAD+ tirzepatide combines tirzepatide's dual GLP-1 and GIP receptor agonism with nicotinamide adenine dinucleotide (NAD+) precursors designed to boost cellular energy metabolism. The theoretical benefit: enhanced mitochondrial function may reduce metabolic stress during weight loss. However, side effects predominantly reflect tirzepatide's mechanism, not NAD+ addition.

Clinical data on NAD+-specific tolerability improvement is sparse. Most gastrointestinal and injection-site adverse events stem from GLP-1/GIP signaling, not mitochondrial support. Providers should counsel patients that NAD+ enhancement does not eliminate or substantially reduce traditional tirzepatide side effects; it may offer complementary metabolic support in the context of overall therapy.

Common Side Effects by System: Evidence-Based Breakdown

Tirzepatide-associated side effects cluster around gastrointestinal and injection-site categories. Incidence varies by dose escalation speed, baseline metabolic health, and individual genetic factors. Understanding frequency and timing helps set realistic expectations during the critical first 4–12 weeks of therapy.

Side Effect Category	Typical Incidence	Onset Timeline	Clinical Notes
Nausea	25–40% of users	Days 1–7 after injection	Usually mild to moderate; often resolves week 3–4 with dose titration
Vomiting	5–15% of users	Week 1–2, dose-dependent	Less common than nausea; may indicate rapid dose escalation
Diarrhea	20–30% of users	Week 1–3	Often resolves spontaneously; dietary adjustment may help
Injection-site reactions	10–20% of users	Immediate to 24 hours post-injection	Mild erythema, swelling; rotate injection sites to minimize

Biomarkers and Metabolic Context: Why Individual Response Varies

Side effect severity is not uniform across patients. Baseline metabolic health, inflammatory markers, hepatic function, and kidney clearance influence how quickly tirzepatide accumulates and how the body tolerates GLP-1/GIP signaling. Patients with pre-existing gastroparesis, elevated liver enzymes, or chronic inflammation often report higher nausea incidence.

NAD+ tirzepatide's proposed metabolic support may theoretically benefit patients with low mitochondrial efficiency or elevated oxidative stress markers, though this remains a clinical hypothesis rather than proven advantage. Provider assessment of baseline NAD+, energy metabolism markers, and inflammation status can contextualize tolerability risk and inform dose titration pacing.

Genetic Predispositions and Tolerability: How Precision Testing Informs Your Provider

Research into GLP-1 receptor (GLP1R) and GIP receptor (GIPR) genetic variants suggests certain individuals may experience amplified or dampened GLP-1/GIP sensitivity. The MC4R rs17782313 variant, for example, associates with altered appetite signaling and may influence gastrointestinal symptom severity. These predispositions provide clinical context, not guarantees of side effect magnitude.

PlexusDx's Precision Peptide Genetic Test examines key variants in peptide signaling pathways—including GLP1R, GIPR, and MC4R—to identify genetic predispositions that may support discussion with your provider about expected tolerability, dose escalation strategy, and metabolic response patterns. This conversation helps set realistic timelines and may guide earlier intervention if tolerance becomes challenging.

Safety Considerations: Who Should Proceed Cautiously With NAD+ Tirzepatide

Tirzepatide (with or without NAD+ addition) carries absolute contraindications: personal or family history of thyroid cancer, MEN2 syndrome, severe pancreatitis, or moderate-to-severe kidney disease. Relative cautions include diabetic retinopathy, dehydration risk, and active biliary disease. NAD+ precursors do not override these safety parameters.

Patients on concurrent medications—particularly those affecting gastric motility, hepatic function, or renal clearance—require provider oversight. If you have a history of nausea-related medication discontinuation, rapid GLP-1 dose escalation may not be appropriate. Working with a provider familiar with tirzepatide optimization and genetic context supports safer, more tolerable initiation.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic testing may help provide context on peptide pathway predispositions—including GLP1R sensitivity variants and MC4R appetite-signaling variants—that can inform your provider's discussion about expected side effect patterns and optimal dose escalation timing. Knowing your genetic profile supports a more personalized conversation rather than a one-size-fits-all approach.

The Precision Peptide Genetic Test reveals predispositions in GLP-1 and GIP signaling pathways (GLP1R rs6923761, GIPR rs1800437) and appetite regulation (MC4R rs17782313, FTO rs9939609) that may influence tolerability and metabolic response. These predispositions should be interpreted with a qualified healthcare provider—they predict genetic factors related to peptide pathways, not exact medication response or side effect severity.

Understanding your genetic context enables a more informed conversation with your provider about tirzepatide tolerability, dose titration strategy, and expected metabolic benefits. Combined with baseline biomarker assessment and careful clinical monitoring, this precision approach may help optimize your therapy plan from the start, potentially reducing trial-and-error adjustments.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.